公司代码：600771 公司简称：广誉远 广誉远中药股份有限公司 2019 年半年度报告 二零一九年八月二十四日 广誉远中药股份有限公司 2019 年半年度报告 重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、 准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律 责任。 二、公司全体董事出席董事会会议。 三、本半年度报告未经审计。 四、公司负责人张斌、主管会计工作负责人傅淑红及会计机构负责人（会计主管人员） 侯宽余声明：保证半年度报告中财务报告的真实、准确、完整。 五、经董事会审议的报告期利润分配预案或公积金转增股本预案 无 六、前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承 诺，敬请投资者注意投资风险。 七、是否存在被控股股东及其关联方非经营性占用资金情况 否 八、是否存在违反规定决策程序对外提供担保的情况？ 否 1 广誉远中药股份有限公司 2019 年半年度报告 九、重大风险提示 报告期内，不存在对公司生产经营产生实质性影响的特别重大风险。公司已在本报 告中详细阐述公司在生产经营过 ...

证券代码：600771 证券简称：广誉远 编号：临 2019-045 广誉远中药股份有限公司 关于参加 2019 年青海地区上市公司 投资者集体接待日活动的公告 | --- | --- | |------------------------------------------------------------------------|-------| | | | | 特别提示 | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 | | | 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | | 重要内容提示： 时间：2019 年 6 月 21 日（星期五）15:00～17:00 方式：网络互动方式 活动登陆网址：青海地区上市公司投资者关系互动平台 http://rs.p5w.net 一、会议类型 为进一步推动上市公司持续做好投资者管理工作，加强与广大投资者的沟通交流， 广誉远中药股份有限公司（以下简称"公司"）将于 2019 年 6 月 21 日（星期五）下 午参加青海地区上市公司投资者集体接待日活动，就公司 2018 年度财务状况、经营成 果、公司治理、规 ...

公司代码：600771 公司简称：广誉远 广誉远中药股份有限公司 2019 年第一季度报告 二〇一九年四月三十日 广誉远中药股份有限公司 2019 年第一季度报告 目 录 一、 重要提示 | --- | --- | |-------|-------------------| | | | | | | | | 二、 公司基本情况 | | | 三、 重要事项 | | | 四、 附录 | 1 广誉远中药股份有限公司 2019 年第一季度报告 单位：元 币种：人民币 一、重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人张斌、主管会计工作负责人傅淑红及会计机构负责人（会计主管人员） 侯宽余保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | |--------------------------------------- ...

Financial Performance - The company's operating revenue for 2018 was CNY 1,618,764,010.55, representing a 38.51% increase compared to 2017[30]. - The net profit attributable to shareholders for 2018 was CNY 374,108,052.45, reflecting a growth of 57.98% year-over-year[30]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 376,468,010.55, an increase of 81.43% from the previous year[30]. - The basic earnings per share for 2018 was CNY 1.06, up 58.21% from CNY 0.67 in 2017[31]. - The weighted average return on net assets for 2018 was 17.81%, an increase of 4.85 percentage points compared to 2017[34]. - The total assets at the end of 2018 were CNY 3,078,858,116.98, a 22.29% increase from the end of 2017[30]. - The net assets attributable to shareholders at the end of 2018 were CNY 2,287,570,596.66, reflecting a 19.53% increase year-over-year[30]. - The company reported a net cash flow from operating activities of -CNY 297,970,259.63 for 2018, indicating a decline compared to -CNY 183,673,210.35 in 2017[30]. - The company achieved a total revenue of CNY 1,618,764,010.55, representing a 38.51% increase compared to the previous year[96]. - The net profit attributable to shareholders reached CNY 374,108,052.45, marking a 57.98% growth year-over-year[100]. Audit and Compliance - The company has received a standard unqualified audit report from Lianda Certified Public Accountants[6]. - The company’s financial report has been confirmed to be true, accurate, and complete by its management[6]. - The company has not engaged in any non-operational fund occupation by controlling shareholders or related parties[9]. - The company has appointed Lianda Certified Public Accountants as its auditing firm[29]. Risks and Challenges - There are no significant risks that materially affect the company's operations during the reporting period[11]. - The company has detailed various risks it may face in its operations, including industry policy risks and market competition risks[11]. Market and Sales Strategy - The company is focusing on strategic cooperation with top 100 chain stores to enhance market development and product marketing strategies[34]. - The company's marketing strategy included a comprehensive rollout of "Good Pregnancy China" and offline promotional activities, enhancing brand effect and driving sales growth[57]. - The company signed contracts with over 220 first-level distributors and 700 second-level distributors, enhancing nationwide product distribution[76]. - The "Good Pregnancy China" project was launched in over 100 chain stores, with more than 5,000 training sessions conducted nationwide[80]. - The company expanded its marketing strategy by integrating resources and enhancing collaboration with top 100 chain stores[80]. - The company received multiple awards, including "Top 10 Innovative Brands in the Industry" and "2018 Annual Influence Brand Award" for its marketing efforts[84]. Research and Development - The company invested CNY 61,241,300 in research and development, with a total of 36 projects initiated or completed during the reporting period[88]. - The company completed 4 R&D projects in the reporting period, with a total of 36 projects in progress, including clinical studies for treating cognitive dysfunction and endometriosis[184]. - The total R&D investment for the year was 61.24 million RMB[184]. - The company has established a joint laboratory for the secondary development of classic prescriptions, enhancing its R&D capabilities[194]. - The company aims to diversify its product structure and enhance market competitiveness through increased R&D efforts[195]. Product Portfolio and Sales - The company has 104 drug registration certificates and 19 patents, indicating a strong product portfolio in the traditional Chinese medicine sector[44]. - Traditional Chinese medicine sales reached 1,281.09 million yuan, a year-on-year increase of 34.83%[81]. - Premium Chinese medicine sales amounted to 213.19 million yuan, growing by 52.93% year-on-year[81]. - Health wine sales achieved 52.56 million yuan, with a significant year-on-year growth of 106.49%[84]. - The company’s medicinal products are primarily sold through a buyout sales model to wholesalers and retail pharmacies[54]. - The company has over 100 traditional Chinese medicine products approved, including "Gui Ling Ji" and "Ding Kun Dan," which are recognized as national secret varieties and included in the national intangible cultural heritage list[155]. Financial Position and Assets - The company's cash and cash equivalents decreased by 55.44% due to investments in new traditional Chinese medicine projects and a research center, totaling 192.5 million yuan[62]. - Accounts receivable increased by 82.00%, attributed to sustained growth in operating revenue[62]. - Inventory rose by 104.74%, driven by strategic procurement of high-value medicinal materials and increased stock for market sales, totaling an increase of 161.4 million yuan[62]. - Fixed assets surged by 1,126.66% as a result of the completion of new projects, with 614 million yuan transferred from construction in progress[62]. Industry Overview - The pharmaceutical manufacturing industry in China achieved a total sales revenue of CNY 2.40 trillion in 2018, growing by 12.6% year-over-year[57]. - The total profit for the pharmaceutical manufacturing industry was CNY 309.42 billion, an increase of 9.5% compared to the previous year[57]. - The pharmaceutical industry in China experienced a value-added growth rate of 10.2%, surpassing the overall consumer goods industry growth by 4.3 percentage points[58]. - The per capita GDP in China reached 64,644 yuan in 2018, reflecting a 6.1% increase from 2017, contributing to a shift in consumption patterns towards healthcare and wellness[58]. - The traditional Chinese medicine industry is projected to reach a market size of 3 trillion yuan by 2020, with an annual compound growth rate of 20%[147].

Financial Performance - In 2018, the company's operating revenue reached ¥1,618,764,010.55, representing a 38.51% increase compared to 2017[30]. - The net profit attributable to shareholders was ¥374,108,052.45, marking a 57.98% increase from the previous year[30]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥376,468,010.55, an increase of 81.43% year-on-year[30]. - The company's total assets at the end of 2018 were ¥3,078,858,116.98, a 22.29% increase from the end of 2017[30]. - The basic earnings per share for 2018 was ¥1.06, up 58.21% from ¥0.67 in 2017[31]. - The weighted average return on net assets increased to 17.81%, up 4.85 percentage points from 2017[34]. - The net cash flow from operating activities was negative at -¥297,970,259.63, worsening from -¥183,673,210.35 in 2017[30]. - The company's cash and cash equivalents decreased by 55.44% due to investments in new traditional Chinese medicine projects and a research center, totaling 192.5 million yuan[62]. - Accounts receivable increased by 82.00%, attributed to continuous growth in operating revenue[62]. - Inventory rose by 104.74%, driven by strategic procurement of high-value raw materials and increased stock for market sales, totaling an increase of 161.4 million yuan[62]. - Fixed assets surged by 1,126.66% as a result of the completion of new projects, with 614 million yuan transferred from construction in progress[62]. - The company reported a net cash flow from operating activities of CNY -297.97 million, indicating a decline compared to the previous year[97]. - The company's total assets saw a significant change, with cash and cash equivalents decreasing by 55.44% to ¥125,175,826.27[140]. - Accounts receivable increased by 61.75% to ¥1,582,145,328.34, reflecting the growth in sales revenue[140]. - Inventory surged by 104.74% to ¥373,359,496.11, driven by strategic procurement of high-value medicinal materials[140]. Audit and Compliance - The company has received a standard unqualified audit report from Lianda Certified Public Accountants[6]. - The company’s financial report has been confirmed to be true, accurate, and complete by its responsible persons[6]. - The company has appointed Lianda Certified Public Accountants as its auditing firm[29]. - The company has not engaged in any non-operational fund occupation by controlling shareholders or related parties[9]. Market and Industry Insights - The pharmaceutical manufacturing industry in China achieved a total sales revenue of CNY 2.40 trillion in 2018, growing by 12.6% year-on-year[57]. - The profit total for the pharmaceutical manufacturing industry was CNY 309.42 billion, marking a 9.5% increase from the previous year[57]. - The pharmaceutical industry in China saw a value-added growth rate of 10.2%, surpassing the overall consumer goods industry growth by 4.3 percentage points[58]. - The per capita GDP in China reached 64,644 yuan in 2018, reflecting a 6.1% increase from 2017, contributing to a shift in consumption patterns towards healthcare and wellness[58]. - The pharmaceutical manufacturing industry's value-added growth is projected to reach approximately 8% in 2019, with main business revenue expected to hit around 278.3 billion yuan, a year-on-year increase of about 15%[58]. - The Chinese medicine industry is projected to reach a market size of over 3 trillion yuan by 2020, with an annual compound growth rate of 20%[147]. - The top five Chinese medicine companies accounted for 42.41% of the total revenue of 232.32 billion yuan generated by 70 listed Chinese medicine companies in the first three quarters of 2018[151]. - The Chinese medicine industry is experiencing a new development phase, with the total output value of the Chinese medicine industry reaching 844.2 billion yuan, accounting for one-third of the entire pharmaceutical industry[147]. Product and R&D Development - The company has 104 drug registration certificates and 19 patented technologies, indicating a strong product portfolio[44]. - The company’s core products have been recognized as part of national intangible cultural heritage, enhancing its brand value[44]. - The company has 36 ongoing and completed R&D projects with a total investment of CNY 61.24 million during the reporting period[88]. - The company completed the construction of the new Traditional Chinese Medicine Industry Project with a total investment of CNY 63.75 million, which passed GMP certification in August 2018[92]. - The company is focusing on high-quality traditional Chinese medicine strategies and enhancing product value through collaborations with universities and research institutions[181]. - Major R&D projects include clinical studies for Dingkun Dan and Gu Ling Ji, focusing on various health conditions, with significant investments in non-clinical safety evaluations and multi-center clinical trials[193]. - The company plans to continue existing R&D projects and explore new production processes and quality stability for traditional products in 2019[194]. - The company aims to establish a diversified product structure and system through its ongoing R&D initiatives[194]. - The company has established a joint laboratory with Shanghai University of Traditional Chinese Medicine and Xiamen University to enhance R&D efforts[1]. Marketing and Sales Strategy - The company integrated marketing resources and strengthened strategic cooperation with top 100 chains, enhancing brand influence and product awareness[34]. - The company's marketing strategy included a comprehensive rollout of "Good Pregnancy China" and offline promotional activities, enhancing brand effect and driving sales growth[57]. - The company expanded its hospital terminal network by adding over 1,200 new hospitals during the reporting period[79]. - The "Good Pregnancy China" project was launched in over 100 chain stores, with more than 5,000 training sessions conducted nationwide[80]. - The company signed contracts with over 220 first-level distributors and 700 second-level distributors to enhance product distribution across the country[76]. - The company organized over 310 academic conferences and 510 departmental promotion meetings to strengthen its academic presence[79]. - The company has established nearly 15,000 chain store coverage nationwide, managing around 40,000 terminals[80]. - The company is actively expanding its distribution network through the "Hundred Stores and Thousand Shops" initiative, enhancing accessibility to high-quality Chinese medicine[160]. - The company is leveraging the "Xinglin No. 1" internet + Chinese medicine O2O service platform to adapt to the growing internet healthcare market[165]. Human Resources and Workforce - The workforce increased to 3,115 employees, a net addition of 941 employees compared to the previous year[92]. - The company emphasized strategic human resource management to support rapid growth and enhance organizational capabilities[92]. - The number of R&D personnel increased to 318, representing 10.21% of the total workforce[1]. Awards and Recognition - The company received multiple awards in 2018, including the "Top Ten Innovative Brands in the Industry" and "Most Growth-Oriented Listed Company in the Biopharmaceutical Industry"[84]. - The "Yuanji Tu" trademark has been recognized as a well-known trademark at both national and provincial levels[71]. - The company has a strong brand advantage, being one of the oldest Chinese medicine enterprises with a history of 478 years, recognized as a "Chinese Time-honored Brand" by the Ministry of Commerce[155]. Financial Management - The company has established a strict accounts receivable management system to ensure the safety of receivables recovery, with a bad debt provision ratio that is at a moderate level compared to peers[142]. - The company has not signed long-term agreements with suppliers, mitigating risks associated with large procurement dependencies[128]. - The company implemented a cash dividend during the reporting period, resulting in a decrease of ¥792.80 million in cash flow from financing activities[139].

公司代码：600771 公司简称：广誉远 广誉远中药股份有限公司 2018 年第三季度报告 二○一八年十月二十七日 | 一、重要提示 | 2 | | --- | --- | | 二、公司基本情况 | 2 | | 三、重要事项 | 5 | | 四、附录 | 7 | 广誉远中药股份有限公司 2018 年第三季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比 | | --- | --- | --- | --- | | | | | 上年度末增减(%) | | 总资产 | 2,708,084,949.57 | 2,517,620,674.29 | 7.57 | | 归属于上市公司股东的净资产 | 2,125,748,199.94 | 1,913,826,432.98 | 11.07 | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减(%) | | | （1-9 月） | （1-9 月） | | | 经营活动产生的现金流量净额 | -269,909,092.42 | -226,170,621.32 | 不适用 ...

公司代码：600771 公司简称：广誉远 广誉远中药股份有限公司 2018 年半年度报告 二零一八年八月二十八日 广誉远中药股份有限公司 2018 年半年度报告 重要提示 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承 诺，敬请投资者注意投资风险。 否 1 一、本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、 准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律 责任。 二、公司全体董事出席董事会会议。 三、本半年度报告未经审计。 四、公司负责人张斌、主管会计工作负责人傅淑红及会计机构负责人（会计主管人员） 侯宽余声明：保证半年度报告中财务报告的真实、准确、完整。 五、经董事会审议的报告期利润分配预案或公积金转增股本预案 无 六、前瞻性陈述的风险声明 √适用 □不适用 七、是否存在被控股股东及其关联方非经营性占用资金情况 否 八、是否存在违反规定决策程序对外提供担保的情况？ 广誉远中药股份有限公司 2018 年半年度报告 九、重大风险提示 报告期内，不存在对公司生产经营产生实质性影响的特别重大风险。公司已在本报 告中详细阐述公司在生产经营过 ...

公司代码：600771 公司简称：广誉远 广誉远中药股份有限公司 2018 年第一季度报告 二○一八年四月二十四日 | 一、重要提示 2 | | --- | | 二、公司基本情况 2 | | 三、重要事项 5 | | 四、附录 8 | 广誉远中药股份有限公司 2018 年第一季度报告 一、重要提示 二、公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 单位：股 | 股东总数（户） | | | 12,548 | | | | | --- | --- | --- | --- | --- | --- | --- | | | | 前十名股东持股情况 | | | | | | | 期末持股 | 比例 | 持有 质押或冻结情况 | | | | | 股东名称（全称） | | | 有限售条件 | 股份 | | 股东性质 | | | 数量 | (%) | 股份数量 | 状态 | 数量 | | | 西安东盛集团有限公司 | 81,991,639 | 23.22 | 27,943,374 | 质押 | 53,560,000 | 境内非国有 | | | | | | | | 法人 | | 财富证券-浦发银行-财富证券-广誉远安 ...

本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承 诺，敬请投资者注意投资风险。 公司代码：600771 公司简称：广誉远 广誉远中药股份有限公司 2017 年年度报告 二○一八年四月二十四日 广誉远中药股份有限公司 2017 年年度报告 重要提示 经利安达会计师事务所（特殊普通合伙）审计确认，公司2017年度实现归属于母公 司所有者的净利润23,680.48万元，年末累计未分配利润（母公司）为-62,034.00万元。 由于累计未分配利润为负，不具备分配条件，因此本年度不进行利润分配，也不进行资 本公积金转增股本，本年度收益全部用来弥补以前年度亏损。 六、前瞻性陈述的风险声明 √适用 □不适用 七、是否存在被控股股东及其关联方非经营性占用资金情况 否 八、是否存在违反规定决策程序对外提供担保的情况？ 否 1 一、本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准 确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责 任。 二、公司全体董事出席董事会会议。 三、利安达会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、公司负 ...

公司代码：600771 公司简称：广誉远 广誉远中药股份有限公司 2017 年第三季度报告 二〇一七年十月二十一日 $$\begin{array}{r l}{\mathbb{H}}&{{}{\overline{{\frac{1}{M}}}}}\end{array}$$ | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 5 | | 四、 | 附录 | 10 | 广誉远中药股份有限公司 2017 年第三季度报告 一、重要提示 二、公司基本情况 2.1 主要财务数据 | | 本报告期末 | | 上年度末 | 本报告期末比 上年度末增减(%) | | | --- | --- | --- | --- | --- | --- | | 总资产 | 2,196,298,404.06 | | 2,142,868,553.28 | | 2.49 | | 归属于上市公司股东的净资产 | 1,811,841,822.95 | | 1,708,248,137.69 | | 6.06 | | | 年初至报告期末 | | 上年初至上年报告期末 | ...